post

CREDENCE Trial PODCAST: Can-I-get-a-flozin?

The CREDENCE trial was published in the NEJM last month and it has made some waves in the world of diabetes management. The headlines state that this SGLT2 drug can reduce the progression of diabetic nephropathy. That is big news indeed. So, what do I think about this new data for a drug that had […]